69 results about "Hepatovirus" patented technology

The invention relates to the field of immunology, and particularly discloses a hepatitis B virus specific TCR combination and application, the hepatitis B virus specific TCR combination is used for recognizing HBV antigen epitopes, the hepatitis B virus specific TCR combination comprises a plurality of separated TCRs, the plurality of separated TCRs form two TCR groups, and the two TCR groups comprise a first TCR group and a second TCR group; wherein the first TCR group specifically recognizes a first antigen epitope, and the amino acid sequence of the first antigen epitope is as shown in SEQ ID NO: 1; the first TCR group specifically recognizes a first antigen epitope, the second TCR group specifically recognizes a second antigen epitope, the amino acid sequence of the second antigen epitope is shown as SEQ ID NO: 2, the second antigen epitope respectively and correspondingly recognizes different antigen epitopes, the hepatitis B virus specific TCR and the epitope thereof are screened out, and an important means can be provided for treatment of TCR-T immune cells infected by hepatitis B virus.

The invention discloses an application of a combination of entecavir, an ASO drug, an mRNA therapeutic vaccine and / or interferon in preparation of drugs for treating chronic hepatitis B. Entecavir and interferon have an antiviral effect, the ASO drug reduces hepatitis B surface antigen titer, and the mRNA therapeutic vaccine is high in immunization speed, so that the entecavir, ASO drug, mRNA therapeutic vaccine and / or interferon combination can inhibit virus replication, and can be used for treating chronic hepatitis B. The composition strikes hepatitis B virus from multiple angles and multiple levels, achieves a good, lasting and non-rebound antiviral effect, and can cure hepatitis B to a certain extent.

The invention belongs to the technical field of biological medicines, and particularly relates to an mRNA vaccine for preventing or treating hepatitis B virus infection and application of the mRNA vaccine. The mRNA vaccine comprises mRNA for coding hepatitis B virus surface antigen or / and hepatitis B virus core associated antigen or / and hepatitis B virus front surface antigen 1 fusion IgG Fc segment protein, and the mRNA is wrapped by lipid nanoparticles to form a delivery system to be prepared into the mRNA vaccine. The vaccine preparation can specifically enhance humoral immune response and cellular immune response aiming at hepatitis B virus surface antigen or / and hepatitis B virus core related antigen or / and hepatitis B virus front surface antigen, and can be used for preventing and treating hepatitis B. All the components in the vaccine preparation can be widely obtained, the vaccine cost is effectively reduced, the vaccine yield is increased, and therefore the vaccine preparation has good practical application value.

2'-Fluoro-6'-methylene-carbocyclic adenosine (FMCA, 21) and its phosphoramidate prodrug (FMCAP, 31) have demonstrated potential anti-HBV activity against both adefovir- resistant as well as lamivudine-resistant double (rtL180M / rtM204V) mutant hepatitis B virus (HBV). In addition, in vitro, these molecules have reinstated a significant activity against lamivudine / entecavir triple mutants (L180M+S202G+M204V). This invention is directed to compounds, pharmaceuticals and methods of treating HBV infections, especially including infections caused by resistant and multiple resistant HBV. Pursuant to the present invention, a complete structure-activity relationship (SAR) of 2'-fluoro-6'-methylene-carbocyclic derived nucleos(t)ides has been evaluated and that analysis is presented herein. Pursuant to the present invention, the synthesis and antiviral evaluation of purine and pyrimidine-derived nucleosides have been reported against wild-type and various HBV mutants. Guanosine analog (FMCG, 25) demonstrated an EC50 value of 0.217μM and cytosine analog (FMCC, 41) expressed a potent EC50 value of 0.0025 μM compared to entecavir (EC50 = 0.0029) against wild-type HBV. Additionally, FMCC (41) maintains its antiviral potency against various HBV mutants. Furthermore, chiral pure FMCAP Sp (34) isomer demonstrated an EC50 value of 1.3 nM and was more potent against several HBV mutants than entecavir.

The application discloses a low-cost hepatitis B (HBV) virus nucleic acid rapid detection method based on a functionally modified paper base, and can realize rapid detection of HBV virus nucleic acid.The method comprises the following steps: (1) pre-amplifying HBV virus nucleic acid to obtain Texas red-labeled nucleic acid; (2) capturing and enriching the Texas red-labeled nucleic acid by using a functionally modified paper base; and (3) performing signal detection.The functionally modified paper base is modified with a fusion protein containing a TR512 polypeptide.The protein functionally modified paper base is simple in preparation, fast in nucleic acid detection time and low in detection cost.

The invention discloses a method for predicting the survival state of duck against hepatitis A virus infection. The method comprises the following steps: (1) constructing a PCA (Principal Component Analysis) prediction model by taking the contents of IFN-alpha and IFN-beta of duck blood as variables; (2) measuring the contents of IFN-alpha and IFN-beta in the duck blood to be measured; and (3) substituting the measured contents of IFN-alpha and IFN-beta in the duck blood into the prediction model, and predicting the anti-hepatitis A virus infection survival state of the duck to be detected according to the family background of the individual in combination with the output result of the prediction model. According to the method, ROC curves and corresponding AUC values of different prediction models in the aspect of predicting the survival state are compared, and the result shows that the AUC value of the PCA prediction model is the highest, and the sensitivity and the specificity are most prominent. Based on the prediction model provided by the invention, the Beijing duck individuals or strains with strong disease resistance can be rapidly screened, and the prediction model has an application prospect in duck disease resistance breeding or duck virus hepatitis prevention.

The present disclosure relates to a ribavirin derivative-embedded double-stranded siRNA analogue, a conjugate comprising the same, and salts and uses thereof. The double-stranded siRNA analogue, the conjugate comprising the same, and the salts thereof of the present disclosure can effectively inhibit multiple viral indicators such as hepatitis B virus DNA, pgRNA, S antigen, E antigen, etc., and provide an effective and feasible method for the treatment of hepatitis B.

This invention discloses a kit for in vitro quantitative detection of hepatitis B virus large surface protein (LHBS). This kit includes multiple monoclonal antibodies, each with its own binding specificity to specific regions of LHBS, thereby improving the sensitivity and dynamic range of LHBS detection in biological samples. Secondly, this invention also provides a set of biological markers targeting specific regions of LHBS, and the monoclonal antibodies can specifically identify this set of biomarkers, enabling non-invasive analysis of HBV infection stages and liver cancer prognosis in biological samples. Furthermore, this invention also provides a set of monoclonal antibodies that, by detecting biomarkers in desired subjects, can predict, diagnose, or treat chronic liver disease.

The invention discloses a traditional Chinese medicine composition for treating fatty liver and reducing hepatitis B virus load. The traditional Chinese medicine composition is prepared from the following raw material medicines: prepared rehmannia root, rhizoma polygonati (processed), radix asparagi, schisandra chinensis, hawthorn leaf, glossy privet fruit, oriental wormwood, radix curcumae, illicium verum and salvia miltiorrhiza. According to the technology of the invention, liver treatment is a preparation based on compatibility of traditional Chinese medicine syndrome differentiation in which liver, spleen and kidney are treated at the same time, fat in the liver can be effectively removed, damage of hepatitis B virus to the liver can be reduced, hepatitis B virus reproduction can be effectively inhibited, the load of hepatitis B virus can be reduced, and multiple curative effects of liver treatment, liver nourishing and liver protection can be realized; the traditional Chinese medicine composition is superior to other treatment medicines and treatment technologies for fatty liver in modern medicine. The method can be widely applied to the fields of medicines, functional foods, health-preserving and health-care products, common foods and beverages and the like.

The present invention relates to the field of biotechnology and discloses a nucleic acid targeting hepatitis B virus and its uses. The nucleic acid of the present invention can effectively inhibit the replication of hepatitis B virus in vitro and in vivo. By applying the RNA interference technology of the nucleic acid of the present invention, specific degradation of HBV mRNA is triggered through targeting, thereby inhibiting the protein expression and virus replication of HBV. It has the advantages of strong specificity, small side effects, and long-lasting drug effect, and also provides a new treatment method for completely clearing HBV genes and curing hepatitis B.

The invention relates to the technical field of antigen detection, and provides a hepatitis B virus surface antigen detection device, which comprises a detection table and a door body, the top of the detection table is provided with a first built-in cavity, and the interior of the detection table below the first built-in cavity is provided with a second built-in cavity. By arranging a fixing structure, a test tube with a to-be-detected reagent is moved between spring pieces to be pressed downwards, the test tube can be clamped under the action of the spring pieces, the test tube is prevented from displacing in a fixing cylinder, at the moment, a clamping block is moved into a movable groove, and under the elastic force action of a second reset spring, the test tube can be clamped in the movable groove. A clamping block is moved into a clamping groove, a test tube is pressed, a reset plate and a fixing cylinder are separated from each other, under the elastic force action of a first reset spring, the reset plate drives the test tube to move upwards through a spring piece, the test tube is conveniently taken out, and the function that the device is convenient to fix is achieved; therefore, the applicability of the hepatitis B virus surface antigen detection device in use is improved.

The invention discloses an efficient production process of an umbilical cord mesenchymal stem cell preparation in the field of stem cells, which comprises the following steps: S101, collection and separation of umbilical cord mesenchymal stem cells: under a sterile condition, separating Walton's jelly by adopting a tissue block culture method, taking out an umbilical cord from an umbilical cord bottle, transferring the umbilical cord into a sterile culture dish, and reserving a sample of a protective solution in the umbilical cord bottle for sterile detection; washing the umbilical cord with normal saline, cutting off two ends of the umbilical cord, discarding the umbilical cord, segmenting the umbilical cord for about 3-4cm, washing to remove blood, umbilical cord veins, two arteries and amniotic membranes, collecting the Walton's jelly, and transferring the Walton's jelly into a 50ml centrifugal tube; adding a small amount of the culture medium, cutting the Walton's gum into pieces with a size of about 1mm < 3 > by using scissors, and centrifugally washing for two times by using normal saline; the preparation produced by the invention is negative in detection of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, syphilis antibody, cytomegalovirus and mycoplasma, and is high in extraction efficiency and convenient to popularize.

The invention discloses a bipyrimidine heterocyclic compound and a preparation method and application thereof, the bipyrimidine heterocyclic compound has a structure as shown in a formula (I), and the invention also provides a pharmaceutical composition containing the compound or a stereoisomer, a medicinal salt, a hydrate, a solvate or a crystal thereof. The invention also discloses application of the compounds in preparation of drugs for treating hepatitis B virus infection, and particularly the compounds can be used as PAPD5 / 7 enzyme inhibitors and hepatitis B RNA non-stabilizers for treating hepatitis B viruses. The compound provided by the invention has the characteristics that the concentration of hepatitis B surface antigen and hepatitis B DNA and RNA can be remarkably reduced, and the probability of functional healing of hepatitis B can be remarkably improved by clinically combining with nucleoside drugs, oligonucleotide drugs / PD-L1 compounds and the like.

To provide a COPS3 inhibitor to be used in treating HBV infection particularly chronic HBV infection.SOLUTION: Provided is use of a COPS3 inhibitor for destabilizing a cccDNA (covalently closed circular DNA) such as an HBV cccDNA. Also provided is a nucleic acid molecule which is complementary with COPS3, and can reduce a COPS3 mRNA level. A pharmaceutical composition and use thereof in treating HBV infection are also included.SELECTED DRAWING: None

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

The invention discloses a screening method of hepatitis B virus antigen epitope peptides, computer equipment and a storage medium, and the method comprises the following steps: generating an initial screening library based on all proteome sequences of hepatitis B viruses, the initial screening library comprising a plurality of antigen epitope peptides to be screened; an antigen epitope peptide-MHC compound corresponding to each antigen epitope peptide is constructed; based on the antigen epitope peptide-MHC compound, a conformational trajectory of the antigen epitope peptide-MHC compound is obtained through molecular dynamics simulation; calculating the binding free energy of each antigen epitope peptide and the MHC based on the conformation trajectory, and sorting the plurality of antigen epitope peptides based on the binding free energy to obtain a first sorting set; based on the antigen epitope peptide-MHC compound, sorting the plurality of antigen epitope peptides by using a machine learning model to obtain a second sorting set; and screening the plurality of to-be-screened antigen epitope peptides based on the first sorting set and the second sorting set to obtain the screened antigen epitope peptides.

The present disclosure is directed to novel compounds, salts thereof, compositions, and methods of using as well as synthesizing. The present disclosure is directed, at least in part, to compounds for the treatment of Hepatitis B (HBV) infection and compositions prepared therefrom. Methods of making and using the compounds for the treatment of Hepatitis B (HBV) infection are also provided.

The invention discloses a sample liquid experiment table for hepatitis C virus detection, and relates to the technical field of virus detection, the sample liquid experiment table comprises a shell, a lifting mechanism and a cleaning mechanism; an opening is formed in the upper end of the shell, and a partition plate is horizontally fixed in an inner cavity; the mounting end of the driving assembly is fixed to the inner bottom wall of the shell, and the output end of the driving assembly penetrates through the partition plate. The pressing rod is fixed on the driving assembly; the placement plate and the detection mechanism can form a sealed space, and the bottom wall of the placement plate is fixedly connected with the output end of the driving assembly; the mounting end of the transmission assembly is fixed to the inner side wall of the shell, and the transmission end of the transmission assembly penetrates through the partition plate to be fixed to the elastic telescopic mechanism. The push plate surface is fixed at the other end of the transmission assembly; one end of the pressing plate is fixed to the transmission assembly, and the other end abuts against the pressing rod. In the hepatitis C detection process, it can be guaranteed that direct contact between an operator and a test tube can be reduced as much as possible in the detection process or after detection is completed, and some potential risks of the operator are avoided.

The present invention relates to the field of pathogen detection, in particular to a primer-probe set, gene chip, kit and application for detecting seven kinds of waterfowl infectious disease pathogens. The primer-probe set provided by the present invention can simultaneously detect goose parvovirus, duck viral enteritis virus, Muscovy duck parvovirus, duck hepatitis A virus type 1, duck hepatitis A virus type 3, duck Tembusu virus and novel duck reovirus, and has strong specificity and high sensitivity. Further, the gene chip prepared by using the primer-probe set provided by the present invention not only has strong specificity and high sensitivity (1.0×10<supgt;0< / supgt> copies / μL), but also has good repeatability and stability, can be stably stored for at least 180 days, and its sensitivity is also better than that of the standard fluorescence quantitative PCR method. It can quickly and efficiently co-detect the above-mentioned main pathogens of waterfowl diseases and can be used for the epidemiological investigation and disease diagnosis of waterfowl.

Provided are a pharmaceutically acceptable salt, a crystal form and a preparation method of a TLR7 / 8 agonist compound of formula I, a pharmaceutical composition containing the pharmaceutically acceptable salt, and a medical use of the pharmaceutically acceptable salt, which can be used for preparing drugs for preventing or treating Toll-like receptor 7 / 8 (TLR7 / 8) related diseases, such as a new therapeutic agent for human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection and cancer.

The present application relates to an immune stimulator and composition and its application and the preparation method of the composition, which can inactivate and eliminate the cells infected with hepatitis B virus on the basis of maintaining the original preventive vaccine hepatitis B virus specific antibody in animals and human bodies, has the dual effects of prevention and treatment; it has stronger immune activation effect than the original HBsAg antigen, which is reflected in the strengthened induction of immune cells, higher antibody production effect, especially the high level of Th1 type immune production marked by gamma-interferon and IgG2a antibody, which has significant innovation and practicability for eliminating hepatitis B virus.

The application provides a hepatitis E virus nucleic acid detection primer, probe and kit, wherein according to a target sequence of a hepatitis E virus gene, a primer and a probe sequence in an asymmetric primer ERA detection system are designed, screened, and optimized in terms of an upstream primer ratio, a downstream primer ratio and an amplification reaction system, so that the primer and the probe can specifically recognize a nucleic acid sequence of the hepatitis E virus, non-specific binding with other irrelevant nucleic acids is reduced, and thus the specificity of detection is improved; meanwhile, efficient amplification of the hepatitis E virus nucleic acid is realized, and even in the case of extremely low content of the virus nucleic acid, the hepatitis E virus nucleic acid can be accurately detected, and thus the sensitivity and the amplification efficiency of detection are improved.

The invention belongs to the technical field of biological detection, and particularly relates to a primer probe combination, a kit and a method for detecting eight porcine viruses. Specific primers and probes are designed for porcine circovirus type 2, porcine circovirus type 3, African swine fever virus, rotavirus, porcine hepatitis E virus, classical swine fever virus, norovirus and fiveleaf virus, and the kit is used for detecting eight viruses of pigs and has the advantages of high specificity, high sensitivity, stable effect and simplicity and convenience in operation; according to the method, eight infection pathogens can be detected, and the method is of great significance to the domestic pig feeding industry and wild boar epidemic disease monitoring and controlling work.

The application discloses an anti-hepatic fibrosis small-molecule compound and application, which is composed of 3beta-ethoxy artenimol and 6-hydroxy kaempferol, and is used as an anti-hepatic fibrosis drug after splenectomy. The application can improve the hepatic fibrosis degree after splenectomy (reduce liver inflammation, improve liver enzyme spectrum, reduce bilirubin, and reduce collagen deposition), and the causes of liver fibrosis include at least one of alcoholic hepatitis, fatty liver, viral hepatitis, drug-induced hepatitis, autoimmune hepatitis and the like.

The invention relates to the discovery of the virus consisting of Opisthorhabdovirus (ORV), Opisthorphenuilivirus (OPLV), Opisthorsivirus (OSV),Clonorsivirus (CSV), Clonorhabdovirus (CRV), Clonorphenuilivirus (CPLV), Schistohaemavirus (ShV), Schistohaematogalivirus (ShTLV), Schistohaemendornavirus (ShMV) and Schistorhabovirus (ShRV) from the Class I carcinogen trematodes Schistosoma haematobium, Opisthorchis viverrini and Clonorchis sinensis and provide evidence of fluke-borne infection of parasitized vertebrate hosts.. The invention provides viruses, nucleic acids, proteins, peptides, and antibodies useful for diagnosis, treatment, and prevention of viral infection and associated diseases.

The application discloses application of coenzyme Q10 and a composition containing coenzyme Q10 in preparation of a medicine for preventing and treating duck hepatitis A virus type 1, and relates to the technical field of veterinary antiviral medicines. The application finds through experiments that coenzyme Q10 and the composition containing coenzyme Q10 have a protective effect on duck hepatitis A virus type 1 infection. The composition contains coenzyme Q10 and egg yolk antibodies. The combination of coenzyme Q10 and egg yolk antibodies can relieve inflammatory reactions caused by duck hepatitis A virus type 1, reduce liver oxidative application, alleviate liver function damage caused by duck hepatitis A virus type 1, and reduce the viral load of duck hepatitis A virus type 1, so that the dual synergy of 'antiviral' and 'anti-inflammatory liver protection' is realized. The application first finds the application value of the combination of coenzyme Q10 and egg yolk antibodies in the prevention and treatment of DHAV-1 infection, and provides a new technical strategy for the prevention and treatment of duck viral hepatitis.

The application discloses a hepatitis B surface antigen specific B cell receptor gene knock-in mouse model, and establishes a hepatitis B virus surface antigen (HBsAg) specific B cell receptor (BCR) gene knock-in mouse model, wherein 70-90% of B cells of the mouse can specifically recognize HBsAg, and differentiate into germinal center B cells and plasma cells. Therefore, the model can be used for basic research on hepatitis B antiviral humoral immune response and tolerance mechanism, and can also be used for application research on development of drugs and vaccines for breaking HBsAg immune tolerance. In summary, the establishment of the model lays a solid foundation for development of a functional cure immune means for hepatitis B.

The invention relates to the technical field of biology, and discloses a DNA molecule containing whole genome cDNA of a live hepatitis A virus attenuated vaccine strain and a preparation method and application of the DNA molecule. Whole-genome infectious cDNA cloning construction is performed on the hepatitis A H2 strain for the first time, and a recovery virus with biological characteristics similar to those of a parent H2 strain is obtained through cDNA cloning rescue obtained through construction, so that a powerful tool is provided for scientific research work and medical application related to hepatitis A viruses and attenuated live vaccines.

The invention provides an integrated DNA interference excluding in-situ hybridization probe and an in-situ hybridization method for detecting hepatitis B virus cccDNA, the in-situ hybridization probe is designed based on a Basescope detection method, and comprises an HBV cccDNA probe specifically targeting an integrated breakpoint of HBV negative chain DNA, an HBV DNA probe targeting an HBV negative chain, an HBV cccDNA probe targeting an HBV negative chain, an HBV cccDNA probe targeting an HBV negative chain, an HBV cccDNA probe targeting an HBV negative chain, and an HBV cccDNA probe targeting an HBV negative chain. The HBV RNA probe with the targeted HBV positive strand gap structure and the matched ribonuclease of the HBV RNA probe can be used for detecting cccDNA and integrating HBV DNA after being treated, and the targeting sequences of the HBV cccDNA, the HBV DNA and the HBV RNA probe are respectively shown as SEQ ID No.1 to SEQ ID No.3. The in-situ hybridization probe and the in-situ hybridization method can be applied to screening medicines for preventing or treating hepatitis B virus infection and researching the life cycle of the hepatitis B virus, so that the understanding on the characteristics of the hepatitis B virus is promoted, and the evaluation on a treatment strategy is optimized.